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Abstract: Osteoporosis is common among older adults and results in costly osteoporotic 
fractures. Screening for this metabolic bone disorder is warranted in most older adults and 
clinicians must be diligent in identifying persons at risk. The evaluation should include an 
assessment of risk factors for falls, a bone density test, and consideration of possible secondary 
causes of osteoporosis. Several medications are available to improve bone density and decrease 
fractures. Adequate calcium and vitamin D intake (and treatment of vitamin D deﬁ  ciency) are 
paramount in the management of osteoporosis.
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Introduction
Osteoporosis is a metabolic bone disorder that affects more than 200 million people 
worldwide. (Lin and Lane 2004) The disease is characterized by low bone mass, which 
makes bones fragile and susceptible to fractures. Osteoporotic fractures are more 
common in the elderly and result in excess morbidity and mortality in this population. 
Despite numerous effective treatments for osteoporosis, many older adults are not 
screened for osteoporosis so consequently they go untreated. To prevent the physical 
and ﬁ  nancial burdens of osteoporotic fractures in the elderly, clinicians must implement 
a comprehensive plan of screening and management of risk factors for osteoporosis. 
Background
Osteoporosis is a systemic bone disorder typiﬁ  ed by low bone mineral density (BMD). 
Although reduced bone mass is a hallmark of the disease, microarchitectural dete-
rioration of bone and increased bone fragility are also present. While the prevalence 
of osteoporosis is more common among some populations (white women, persons 
with low body mass), osteoporosis is seen in all racial and ethnic groups, all weight 
categories, and in both men and women. For residents in skilled nursing facilities, the 
prevalence exceeds 50% regardless of race or gender (Wilkins and Birge 2005).
Osteoporosis and its resulting fractures signiﬁ  cantly increase with age. The primary 
age-related change in bone mass occurs when there is an imbalance in bone formation 
and bone resorption. Instead of a comparable degree of bone formation and resorp-
tion, there is decreased bone formation (osteoblastic activity) and increased bone 
resorption (osteoclastic activity). This shift in bone remodeling usually begins in the 
third decade of life and continues with aging. (Fernández et al 2006) The increased 
osteoclastic activity is signiﬁ  cantly exacerbated by estrogen loss, especially during 
menopause in women.
This age-related bone loss may be additionally affected by both intrinsic and 
extrinsic factors. A list of both modiﬁ  able and nonmodiﬁ  able risk factors for reduced 
bone mass is listed in table 1. It is important to note that while these risk factors 
increase the risk of developing reduced bone mass, osteoporosis commonly occurs in 
older persons without additional risk factors. Many clinicians assume that screening 
need only occur in persons with several of the risk factors listed; however, all older Clinical Interventions in Aging 2007:2(3) 390
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Table 1 Risk factors for osteoporosis
Nonmodiﬁ  able  Modiﬁ  able
Advanced age   Smoking
Female gender   Inadequate calcium intake
White/Asian race   Inadequate vitamin D 
Low peak bone mass  Low body weight (BMI <21 kg/m2)
Family history of osteoporosis  Estrogen deﬁ  ciency
Personal history of fracture  Hypogonadism
Low Body Mass Index  Chronic glucocorticoid therapy
  (see table 3 for other medications)
adults should be screened and persons with multiple risk 
factors should be screened earlier.
Two common misconceptions regarding risk for 
osteoporosis is that only white or Asian women become 
osteoporotic and that men do not develop osteoporo-
sis unless there are secondary causes. Several studies 
have found that women of African descent or African 
Americans also develop osteoporosis. (Bohannon 1999; 
Kleerkoper et al 1994; Wilkins and Goldfeder 2004) In 
fact, African American women, especially those with 
advanced age and lower body mass index (BMI), have 
similar rates of osteoporosis as white women. (Wilkins 
and Goldfeder 2004) Additionally, African American 
women have higher rates of mortality after hip fracture 
than other groups. (Kellie and Brody 1990)
While research has considerably increased over the 
last decade regarding osteoporsis in men, the prevalence 
and impact of osteoporsis in men remains unclear to many 
clinicians. It is estimated that 20% of men over age 50 
will develop an osteoporotic fracture during their lives 
(Melton et al 1998; Kanis et al 2000) and men are more 
likely to suffer an osteoporotic fracture than be diagnosed 
with prostate cancer. (Melton 1995) It appears that due to 
a higher peak bone mass and no substantial loss in estrogen 
(as with menopause), men are likely to develop osteopo-
rosis approximately 10 years after women. Certainly men 
with multiple risk factors for osteoporosis may develop 
the disease sooner.
Why osteoporosis screening 
is important
The obvious goal of screening for and treating osteoporosis 
is to prevent osteoporotic fractures and the functional decline 
that often accompanies these fractures. While reduced 
bone density is a major risk factor for fractures, the risk of 
falling in older adults contributes substantially to osteopo-
rotic fractures, especially nonvertebral fractures. Vertebral 
fractures are the most common osteoporotic fractures and 
account for 70% of all fractures. One in 5 women with an 
asymptomatic or symptomatic vertebral fracture will experi-
ence another vertebral fracture within one year (Lindsay et al 
2001). Presence of a vertebral fracture also increases risk of 
nonvertebral fractures.
While both vertebral and nonvertebral fractures are 
associated with functional decline and increased morbidity, hip 
fractures have the highest rates of functional decline and mor-
tality. Only 25% of hip fracture patients return to their previous 
level of function (Birge et al 1994). The highest incidence of 
hip fractures occurs in nursing home residents, where 50% of 
the residents fall each year (Chandler et al 2000).
Accordingly, identifying risk factors for falls is as 
important as ascertaining BMD in preventing nonvertebral 
fractures. Common risk factors for falls are postural 
instability, cognitive impairment, and gait imbalance. Table 
2 lists other risk factors for falls. Recent studies have also 
found an association between vitamin D deﬁ  ciency and falls 
or postural instability. Additional evidence supports a role 
of vitamin D in neuromuscular function. It is important to 
identify vitamin D deﬁ  ciency in older adults since it may 
affect both bone density and risk for falls.
Screening for osteoporosis
All older adults at risk for osteoporosis should be evaluated 
for osteoporosis and for risk factors for osteoporotic fractures. 
Persons at risk are those over age 65 and those under age 65 
with three or more risk factors (See Table 1). At risk persons 
should have a history and physical examination, BMD test, 
and laboratory testing. The medical history should focus on 
risk factors for low bone density and risks for falls. Ques-
tions regarding family history of osteoporosis or hip fracture, 
personal history of fracture, current or previous smoking, 
excess alcohol use, menopausal status and medication use 
should be asked.
The physical examination should include height and 
weight for body mass index (BMI) and determining any loss 
of height. A BMI of less than 21kg/m2 and a loss of more 
than 5 cm (or 2 inches) are both risk factors for osteoporosis. 
Presence of a gait disorder, lower extremity weakness, and 
postural instability all increase risk for falls and fractures. 
Additionally, evidence of thoracic kyphosis may suggest 
vertebral fractures.
Bone mineral density testing
The National Osteoporosis Foundation recommends that 
all men and women over age 65 have a BMD test. Younger Clinical Interventions in Aging 2007:2(3) 391
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postmenopausal women with 1 additional risk factor should 
also have a BMD test. Persons with hyperthyroidism, hyper-
parathyroidism and those on chronic glucocorticoid therapy 
should also be screened for reduced bone density. Other 
secondary causes of osteoporosis that may warrant screening 
are listed in Table 3.
Osteoporosis screening should ideally be performed using 
dual energy X-ray absorptiometry (DXA) to measure BMD 
of the hip and spine. Currently, central DXA machines are 
widely available and should be used for baseline screening. 
Although some peripheral bone densitometers have been 
found to correlate with central DXA and to predict risk of 
fracture (Bauer et al 1997), a recent meta-analysis ﬁ  nds that 
calcaneal quantitative ultrasound does not reliably exclude 
or conﬁ  rm osteoporosis (Nayak et al 2006). If patients are 
unable to obtain a central DEXA of the hip and spine (the 
person cannot lie comfortably for the exam, exceeds the 
weight limit), a forearm BMD can be performed using 1/3 
of the radius in the nondominant arm. Additionally if the 
patient does not readily have access to the machine or has 
radiopaque implants in the measurement area, clinicians may 
consider using a peripheral machine. Although central BMD 
measurement is preferable, peripheral measurement may be 
useful in screening low risk populations. Whenever possible, 
persons with abnormal peripheral results should subsequently 
have a central DEXA or quantitative CT scan.
When interpreting the BMD results, clinicians should 
refer to the total hip, femoral neck, and lumbar spine. Local 
factors affecting bone density such as weight bearing, muscle 
usage and co-existing osteoarthritis may result in differences 
in BMD categories between bones. The lowest score should 
be used to determine whether the patient is normal, has 
osteopenia or osteoporosis. In persons with normal BMD, 
repeat testing should occur in 3–5 years and in those with 
osteopenia, tests should be repeated in 2 years.
Biochemical measures of bone 
turnover
Biochemical measures (BCM) of bone turnover reﬂ  ect rates 
of bone resorption or bone formation and can be found in 
blood or urine. BCMs may measure products of osteoblasts 
(bone formation) such as osteocalcin or bone-speciﬁ  c alka-
line phosphatase, or they may measure collagen breakdown 
products that reﬂ  ect bone resorption, such as pyridinolines 
or C- or N-terminal telopeptides. Although BCMs are com-
monly used in clinical trials, their clinical usefulness is 
limited due to individual patient variability
If the clinician chooses to use a BCM, those that predict 
bone resorption are most useful (see Table 4) BCMs can 
be used to predict fracture risk and monitor treatment but 
should not be used to diagnose osteoporosis. A decrease 
in resorption markers usually reﬂ  ects a reduction in bone 
remodeling activity. To use BCMs for monitoring, obtain a 
baseline value then recheck every 3 to 6 months until stable. 
Populations that may beneﬁ  t from BCM monitoring include 
diseases with rapid and severe bone loss such as persons using 
chronic glucocorticoid therapy, with hyperparathyroidism 
or hypogonadism. 
Laboratory testing
Routine laboratory tests for the evaluation of osteoporosis 
should include a serum calcium, 25-hydroxy vitamin D, a 
complete blood count, and 24-hour urinary calcium excretion. 
Elevated calcium suggests hyperparathyroidism and decreased 
calcium suggests malabsorption or vitamin D deﬁ  ciency/
resistance. Anemia may indicate multiple myeloma. 
Additional laboratory tests such as parathyroid hormone, 
thyroid-stimulating hormone, and serum protein electropho-
resis may be indicated after the initial evaluation.
Managing risk for osteoporotic 
fractures
The primary goal of treating osteoporosis is prevention 
of osteoporotic fractures. Below are recommendations for 
Table 2 Risk factors for falls and nonvertebral fractures
Gait disorders
Lower extremity muscle weakness
Cognitive impairment/dementia
Neurodegenerative disorders of the central nervous system 
Hypotension 
Vitamin D deﬁ  ciency 
Impaired vision
Impaired hearing
Medications affecting postural stability
Table 3 Common causes of secondary osteoporosis
Endocrine Chronic  drug  therapy
Hypogonadism   Glucocorticoids
Hyperthyroidism   Thyroxine
Anorexia nervosa   Anticonvulsants
Hyperparathyroidism GnRH  agonists 
   Aromatase inhibitors
Nutritional  Other
Malabsorption syndromes  Hypercalciuria
Vitamin D deﬁ  ciency/resistance   Alcoholism
Calcium deﬁ  ciency
GnRH: gonadotropin releasing hormoneClinical Interventions in Aging 2007:2(3) 392
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treating osteoporosis. Pharmacologic treatment should be 
instituted in those with BMD T-scores worse than −2.5 (or 
worse than −2.0 and multiple risk factors) or those with a 
history of vertebral or hip fracture. Recommendations on 
nutrients should be implemented in all older adults regard-
less of BMD.
Nutrition
Treating osteoporosis and osteopenia should begin with 
appropriate supplementation of calcium and vitamin D. 
Calcium has been shown to increase BMD when adminis-
tered with vitamin D and it is co-administered with most 
therapeutic agents for osteoporosis.( Dawson-Hughes et al 
1997) The National Institutes of Health Consensus Panel 
recommends daily dietary intake of calcium is 1,500 mg/day 
for men and women aged 65 and older. Preferably, calcium 
intake should be in the form of dairy products to improve 
absorption. Calcium carbonate and calcium citrate may be 
used as dietary supplements. Additionally, calcium should 
be taken in divided doses to improve absorption.
A meta-analysis of randomized clinical trials in older 
women ﬁ  nds that a vitamin D dose of 700–800 units/day is 
associated with decreased risk of hip fractures. (Bischoff-
Ferrari et al 2005). Studies have also that vitamin D decreases 
fall risk, and improves muscle strength and balance. (Pfeifer 
et al 2000; Prabhala et al 2000; Bischoff et al 2003) It is 
recommended that older adults with normal vitamin D 
status consume 800 units/day of vitamin D. There are very 
few dietary sources of vitamin D (fatty ﬁ  sh such as tuna, 
salmon, mackerel and sardines or cod liver oil) that provide 
100 units or more per serving. Vitamin D fortiﬁ  ed milk 
only contains 100 units of vitamin D per 8 ounce serving. 
Although sunlight is a major source of vitamin D for most 
people, several changes occur in older adults that contrib-
ute to vitamin D deﬁ  ciency including reduced exposure to 
sunlight. Additional recommendations for the management 
of vitamin D deﬁ  ciency are addressed below.
Phosphorus intake is essential to normal bone develop-
ment and mineralization. Although most adults consume 
more than the recommended 700 mg/day of phosphorus, 
10–15% of older adults have inadequate phosphorus intake. 
(Bischoff et al 2003) Vegetarians are at increased risk for 
phosphorus deﬁ  ciency. Caution must be exercised in persons 
with low phosphorus intake who also use calcium carbonate 
or citrate supplements as these may bind phosphorus and cre-
ate a negative phosphorus balance. Alternatively, excessive 
phosphorus intake may disrupt skeletal homeostasis.
Bisphosphonates
Potent antiresorptive agents, bisphosphonates inhibit osteoclast 
activity and reduce bone turnover. This class of drugs increases 
bone density and prevents both vertebral and nonvertebral 
fractures (see Table 5). Of note, relatively small increases 
in BMD may reduce fracture risk by 20 to 50%. (Prabhala 
et al 2000) Unfortunately, most clinical trials have excluded 
patients over age 80, so the beneﬁ  t in this population is unclear. 
In one study of women over age 80, risedronate had no effect 
on hip fractures, but there was an 80% reduction in new 
vertebral fractures at one year (Boonen et al 2004).
Bisphosphonates are associated with esophagitis and 
esophageal/gastric ulcers so the instructions for ingestion 
must be followed carefully to avoid side effects. Osteone-
crosis following dental procedures has also been reported 
in persons using bisphosphonates, mostly those using large 
IV doses for hypercalcemia. Although studies in excess of 5 
years have shown no unexpected adverse effects, theoretical 
concerns regarding oversuppression of bone turnover exist. 
Given this concern, the relatively long half-life of the drugs, 
and evidence that bone turnover may remain suppressed after 
discontinuation of the drug, some clinicians consider giving 
patients a ‘holiday’ from the drugs after 5 years. At this time, 
this is not a recommendation of the manufacturers or the Food 
and Drug Administration and no guidelines for monitoring 
patients off the drugs have been established. 
Selective estrogen receptor modulators 
(SERMs)
The SERM raloxifene has been shown to increase BMD 
in both the spine and hip and to decrease vertebral fracture 
risk by up to 60%. (Ettinger et al 1999) Raloxifene has not 
been shown to decrease hip fractures or other non-vertebral 
fracture risk. Raloxifene has also been found to decrease 
incidence of invasive breast cancer by more than 70%. 
(Cummings et al 1999) Side effects of SERMs include 
thromboembolism and vasomotor symptoms.
Table 4 Biochemical markers of bone turnover
Markers of bone resorption  Markers of bone formation
Pyridinoline Osteocalcin
Deoxypyridinoline  Bone alkaline phosphatase
Type I collagen telopeptides  Propeptide of type I procollagen
N-terminal crosslinking   N-terminal propeptide 
telopeptide (NTX-1)  of type I procollagen
C-terminal crosslinking   C-terminal propeptide 
telopeptide (CTX-1)  of type I procollagen
Tartrate-resistant acid phosphatase
(TRAP) Clinical Interventions in Aging 2007:2(3) 393
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Hormone replacement therapy 
(HRT)
Estrogen therapy has been shown in several studies to 
increase BMD from 2% to 7% at all sites and to prevent both 
vertebral and hip fractures (PEPI 1996; Lindsay et al 2005). 
Unfortunately, HRT has been associated with an increased 
risk of myocardial infarction, stroke, thromboembolism and 
breast cancer. Although low dose oral estrogen or transdermal 
estrogen may minimize or even reduce cardiovascular and 
stroke risk, there is insufﬁ  cient evidence that these agents 
have a beneﬁ  cial effect in decreasing the risk of nonvertebral 
fractures. Accordingly, HRT should be reserved for women 
with signiﬁ  cant symptoms of menopause and should be 
limited to the shortest possible duration.
Parathyroid hormone (PTH)
Teriparatide (recombinant human PTH) is an anabolic agent 
that stimulates osteoblastic bone formation. Teriparatide 
increases bone density from 3% to 9% and decreases vertebral 
fractures by up to 65%. (Neer et al 2001) This agent also 
decreases nonvertebral fractures by 50% but has not been 
shown to speciﬁ  cally decrease hip fractures. Teriparatide is 
administered subcutaneously for up to 2 years.
Calcitonin
Calcitonin inhibits bone resorption and may increase BMD 
in the spine by up to 3%. It has been shown to decrease 
vertebral fractures to a lesser degree the other osteoporosis 
medications and has no beneﬁ  t in preventing hip fractures 
(Chestnut et al 2000). Consequently, calcitonin is generally 
reserved for persons who cannot tolerate other medications. 
Calcitonin has also been found to reduce bone pain from 
vertebral compression fractures.
Treating vitamin D deﬁ  ciency
Vitamin D deﬁ  ciency is common in the elderly and actual 
vitamin D levels vary substantially between individuals. 
Determination of vitamin D status is important in all 
older adults. Serum 25-hydroxyvitamin D measurement is 
recommended since the half-life is longer and there are fewer 
ﬂ  uctuations that seen in 1,25- dihydroxyvitamin D, the bio-
logically active form of vitamin D. Due to possible vitamin D 
resistance, it is helpful to also measure serum PTH levels.
The goal 25-hydroxyvitamin D level is greater than 
30 ng/ml with a PTH of less than 42 pg/ml. (Wilkins and 
Birge 2005) For persons with vitamin D levels less than 
30 ng/ml and/or PTH greater than 42 pg/ml, therapy with 
ergocalciferol, 50,000 units every two weeks, should be 
started. PTH and vitamin D levels should be rechecked in 8 
weeks. The dosing interval should be decreased to weekly if 
the levels are not yet optimal. Once the levels are within goal 
range, vitamin D and PTH should be followed quarterly and 
adjusted as needed. If the patient requires more than 250,000 
units monthly of ergocalciferol, calcitriol orally or injected 
should be considered. Referral to an endocrinologist or bone 
specialist may be indicated.
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